<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210403050824N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-07-11</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>paracetamol and lidocaine in pain of intravenous propofol</public_title>
      <acronym></acronym>
      <scientific_title>Comparative study of prophylactic effect of injectable paracetamol and lidocaine on pain caused by intravenous injection of propofol in children 6 to 10 years</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-07-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/55358</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Random sequence (blocking) is generated by the help of Excel software and blocks of six are used to equalize the three groups so that the intervention groups 1 and 2 or the control of each person included in the study, can be determined randomly and equally. The  blocks of six are separated from the samples and placed in the block randomly by the Excel software of group A or B or C. At the end, it is determined which letter represents the intervention group 1 and 2 and which is for the control group, Blinding description: The drugs are prepared by someone outside the research team in the operating room. He equalize their volumes in ready-made syringes with a coating so that its contents are not known. Group codes are then written on the syringes. The anesthetist who inject the drug and the anesthesiologist who collect the data do not know the group's codes. Patients are also unaware of group assignments. The person who is doing the statistical analysis also does not know how the codes have been assigned to the study groups. After completing the analysis, the codes will be opened.</study_design>
      <phase>3</phase>
      <hc_freetext>Pain induced by intravenous propofol injection..</hc_freetext>
      <i_freetext>Intervention 1: The first intervention group: All patients have been taken to the operating room then after premedication with 0.1 milligram per kilogram of midazolam, intravenous cannula number 20 have been inserted in non-dominant dorsal veins and 10 cc per kilogram of Ringer's lactate serum will be infused . Then the arm will be held higher than body for one minute to drain the blood. The cuff of the sphygmomanometer will be closed on the same arm and inflates up to 20 mmHg above systolic blood pressure. Then 1 milligram per kilogram of Paracetamol will be injected intravenously and the cuff will be emptied after one minute. Finally 2 milligram per kilogram of Propofol is then injected over 15 seconds. During the intervention we will record the patient's vital signs, Heart Rate, Blood Pressure, and movements and speech rate one minute before injection of Propofol and in the first minute after injection in a questionnaire. Intervention 2: The second intervention group: All patients have been taken to the operating room then after premedication with 0.1 milligram per kilogram of midazolam, intravenous cannula number 20 have been inserted in non-dominant dorsal veins and 10 cc per kilogram of Ringer's lactate serum will be infused . Then the arm will be held higher than body for one minute to drain the blood. The cuff of the sphygmomanometer will be closed on the same arm and inflates up to 20 mmHg above systolic blood pressure. Then 1 milligram per kilogram of lidocaine 1% will be injected intravenously and the cuff will be emptied after one minute. Finally 2 milligram per kilogram of Propofol is then injected over 15 seconds. During the intervention we will record the patient's vital signs, Heart Rate, Blood Pressure, and movements and speech rate one minute before injection of Propofol and in the first minute after injection in a questionnaire. Intervention 3: The control group: All patients have been taken to the operating room then after premedication with 0.1 milligram per kilogram of midazolam, intravenous cannula number 20 have been inserted in non-dominant dorsal veins and 10 cc per kilogram of Ringer's lactate serum will be infused . Then the arm will be held higher than body for one minute to drain the blood. The cuff of the sphygmomanometer will be closed on the same arm and inflates up to 20 mmHg above systolic blood pressure. Then 2 cc of normal saline will be injected intravenously and the cuff will be emptied after one minute. Finally 2 milligram per kilogram of Propofol is then injected over 15 seconds. During the intervention we will record the patient's vital signs, Heart Rate, Blood Pressure, and movements and speech rate one minute before injection of Propofol and in the first minute after injection in a questionnaire.ed in a questionnaire.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is The data are not completed yet.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ahmad Karimi hasan abadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 59,Yasaman Ave., Delgosha St., Najaf Abad</address>
        <city>Najafabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8517775899</zip>
        <telephone>+98 31 4274 3155</telephone>
        <email>ahmadkarimi1886@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sedigheh Shahhoseini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 6, Pasandidideh Al, East Allameh Amini St</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8156674943</zip>
        <telephone>+98 31 3261 2181</telephone>
        <email>nasrin20ir@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children 6 to 10 years
general anesthesia with propofol
ASA1,ASA2</inclusion_criteria>
      <agemin>6 years</agemin>
      <agemax>10 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Known liver disease
Known heart disease
Known neurological disease
History of metabolic disease
Drug reactions and allergies</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T88.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other complications of anesthesia</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first intervention group: All patients have been taken to the operating room then after premedication with 0.1 milligram per kilogram of midazolam, intravenous cannula number 20 have been inserted in non-dominant dorsal veins and 10 cc per kilogram of Ringer's lactate serum will be infused . Then the arm will be held higher than body for one minute to drain the blood. The cuff of the sphygmomanometer will be closed on the same arm and inflates up to 20 mmHg above systolic blood pressure. Then 1 milligram per kilogram of Paracetamol will be injected intravenously and the cuff will be emptied after one minute. Finally 2 milligram per kilogram of Propofol is then injected over 15 seconds. During the intervention we will record the patient's vital signs, Heart Rate, Blood Pressure, and movements and speech rate one minute before injection of Propofol and in the first minute after injection in a questionnaire.</i_keyword>
      <i_keyword>The second intervention group: All patients have been taken to the operating room then after premedication with 0.1 milligram per kilogram of midazolam, intravenous cannula number 20 have been inserted in non-dominant dorsal veins and 10 cc per kilogram of Ringer's lactate serum will be infused . Then the arm will be held higher than body for one minute to drain the blood. The cuff of the sphygmomanometer will be closed on the same arm and inflates up to 20 mmHg above systolic blood pressure. Then 1 milligram per kilogram of lidocaine 1% will be injected intravenously and the cuff will be emptied after one minute. Finally 2 milligram per kilogram of Propofol is then injected over 15 seconds. During the intervention we will record the patient's vital signs, Heart Rate, Blood Pressure, and movements and speech rate one minute before injection of Propofol and in the first minute after injection in a questionnaire.</i_keyword>
      <i_keyword>The control group: All patients have been taken to the operating room then after premedication with 0.1 milligram per kilogram of midazolam, intravenous cannula number 20 have been inserted in non-dominant dorsal veins and 10 cc per kilogram of Ringer's lactate serum will be infused . Then the arm will be held higher than body for one minute to drain the blood. The cuff of the sphygmomanometer will be closed on the same arm and inflates up to 20 mmHg above systolic blood pressure. Then 2 cc of normal saline will be injected intravenously and the cuff will be emptied after one minute. Finally 2 milligram per kilogram of Propofol is then injected over 15 seconds. During the intervention we will record the patient's vital signs, Heart Rate, Blood Pressure, and movements and speech rate one minute before injection of Propofol and in the first minute after injection in a questionnaire.ed in a questionnaire.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Patient pain score at baseline and one minute after propofol injection. Timepoint: At baseline when injecting propofol and one minute after injecting propofol. Method of measurement: Propofol injection pain score based on the patient's motor and verbal response.</prim_outcome>
      <prim_outcome>Heart rate at baseline and one minute after propofol administration. Timepoint: At baseline and one minute after propofol injection. Method of measurement: Saadat Standard monitoring.</prim_outcome>
      <prim_outcome>Mean arterial pressure at baseline and one minute after propofol injection. Timepoint: At baseline and one minute after propofol injection. Method of measurement: Saadat Standard monitoring.</prim_outcome>
      <prim_outcome>Patient agitation during propofol injection. Timepoint: At baseline and one minute after propofol injection. Method of measurement: Richmond Agitation scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Isfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-10-17</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Isfahan University of Medical Science., Hezar Jarib Ave., Azadi Sq., Isfahan Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
